Truist Financial Lowers PT on AbCellera Biologics (ABCL) to $10 From $28, Keeps a Buy RatingJuly 7, 2025Yahoo Finance
Truist Financial Lowers PT on AbCellera Biologics (ABCL) to $10 From $28, Keeps a Buy RatingJuly 7, 2025Yahoo Finance
Craig-Hallum Reiterates a Buy Rating on Clover Health Investments (CLOV), Sets a $6 PTJuly 7, 2025Yahoo Finance
Leerink Partners Reiterates a Buy Rating on Akebia Therapeutics (AKBA) With a $7 PTJuly 7, 2025Yahoo Finance
Leerink Partners Reiterates a Buy Rating on Akebia Therapeutics (AKBA) With a $7 PTJuly 7, 2025Yahoo Finance
Why the CEO of the world’s large sovereign wealth fund is worried about rising US debtJuly 7, 2025Yahoo Finance
Why the CEO of the world’s large sovereign wealth fund is worried about rising US debtJuly 7, 2025Yahoo Finance
